title: Therapeutic effects of mosapride citrate and lansoprazole for prevention of aspiration pneumonia in patients receiving gastrostomy feeding.
abstract: BACKGROUND
  Aspiration pneumonia is an emerging problem in patients receiving gastrostomy feeding. This study is designed to clarify the therapeutic effects of mosapride citrate and lansoprazole for prevention of aspiration pneumonia in patients receiving gastrostomy feeding.
  
  
  METHODS
  The study subjects were 119 patients with dysphasia who required gastrostomy feeding. They were randomly assigned to the control (without medication), lansoprazole (15 mg, 1/day), and mosapride (5 mg, 3/day) groups. The number of days with fever (≥37.8 °C), vomiting, and antibiotics administration, as well as the occurrence of pneumonia were investigated during the 6-month observation period.
  
  
  RESULTS
  The incidence of pneumonia during the observation period was significantly lower in the mosapride group as compared to the control (7/38 vs. 16/40, p = 0.038) and lansoprazole (vs. 20/41, p = 0.005) groups. The mosapride group also showed a significant decrease in days with fever and antibiotics administration as compared to the other groups. Multivariate analysis revealed that the presence of hiatal hernia was a significant risk factor and administration of mosapride was a significant preventive factor for pneumonia.
  
  
  CONCLUSIONS
  Mosapride has a preventive effect on occurrence of pneumonia in patients receiving gastrostomy feeding.
authors.affiliation: Department of Internal Medicine, Kasai City Hospital, 1-13 Yokoo, Houjou, Kasai-city, Hyogo, 675-2393, Japan, kent8t8@gmail.com.
authors.forename: Kento
authors.initials: K
authors.lastname: Takatori
authors.forename: Rihito
authors.initials: R
authors.lastname: Yoshida
authors.forename: Aya
authors.initials: A
authors.lastname: Horai
authors.forename: Shinya
authors.initials: S
authors.lastname: Satake
authors.forename: Takayuki
authors.initials: T
authors.lastname: Ose
authors.forename: Naoto
authors.initials: N
authors.lastname: Kitajima
authors.forename: Shushi
authors.initials: S
authors.lastname: Yoneda
authors.forename: Kyoichi
authors.initials: K
authors.lastname: Adachi
authors.forename: Yuji
authors.initials: Y
authors.lastname: Amano
authors.forename: Yoshikazu
authors.initials: Y
authors.lastname: Kinoshita
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D001549:Benzamides / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D004750:Enteral Nutrition; D005260:Female; D005774:Gastrostomy; D006801:Humans; D015994:Incidence; D064747:Lansoprazole / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009025:Morpholines / Q000627:therapeutic use*; D011015:Pneumonia, Aspiration / Q000517:prevention & control*; D011446:Prospective Studies; D017366:Serotonin Receptor Agonists / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000897:Anti-Ulcer Agents; D001549:Benzamides; D009025:Morpholines; D017366:Serotonin Receptor Agonists; D064747:Lansoprazole; C062720:mosapride